Xiangyu Medical has released an announcement regarding abnormal stock price fluctuations, noting that the capital market has recently demonstrated significant enthusiasm for concepts related to brain engineering and brain-computer interfaces. The company's primary focus lies in non-invasive brain-computer interface technology, a path that diverges from the internationally prevalent invasive technology approach. At present, Xiangyu Medical has made specific strategic arrangements in the brain-computer interface sector. Nevertheless, as of the end of 2025, relevant products have not yet attained large-scale sales, and their contribution to the company's revenue remains relatively modest.

During the first three quarters of 2025, the company channeled over 60% of its research and development (R&D) investment into this particular field. Through these efforts, it has achieved independent research and production capabilities in relevant technologies, and has already secured two registration certificates. Building on its established foundation in rehabilitation equipment and comprehensive solutions, the company is well-positioned to integrate 'brain-computer interface technology + its proprietary rehabilitation equipment'. Currently, Xiangyu Medical's brain-computer interface products have already been introduced to more than 500 top-tier hospitals. The company aims to expand its reach to over 1,000 top-tier hospitals by 2026, with expectations of accelerating the commercialization process.